Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapie...
13 January 2020 - 6:00AM
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading
off-the-shelf, allogeneic T-cell immunotherapy company developing
novel treatments for patients with cancer, autoimmune and viral
diseases, today announced President and Chief Executive Officer
Pascal Touchon will share details of the company’s mission,
scientific platform and development pipeline during a presentation
at the 38th Annual J.P. Morgan Healthcare Conference on Thursday,
January 16 at 8:30 a.m. PST at the Westin St. Francis Hotel in San
Francisco.
“As we enter into this new year, we are proud of our progress
building a leading off-the-shelf, allogeneic T-cell immunotherapy
company with a robust pipeline,” said Pascal Touchon, President and
Chief Executive Officer of Atara Biotherapeutics. “Backed by our
innovative EBV T-cell platform, next-generation CAR T technologies,
state-of-the-art manufacturing capabilities and dedication to
developing transformative T-cell immunotherapies for patients, we
are confident in our ability to execute on our 2020 plans.”
Anticipated key milestones across Atara’s four strategic
priorities in 2020 include:
Tab-cel® (tabelecleucel)
- Submitted clinical trial applications (CTAs) to several
European countries in November 2019 to enable opening EU clinical
sites in 2020
- Begin enrollment in a Phase 2 multi-cohort study including
patients with other EBV+ cancers in the second half of 2020
- Initiate FDA Biologics License Application (BLA) submission for
patients with EBV+ PTLD in the second half of 2020
ATA188
- Initiate enrollment of randomized, double-blind,
placebo-controlled Phase 1b study in patients with progressive MS
in the second or third quarter of 2020
- Present six- and twelve-month ATA188 Phase 1a clinical results
for cohorts 3 and 4 in the first and second halves of 2020,
respectively
ATA2271
- Submit next-generation mesothelin-targeted autologous CAR T IND
for patients with advanced mesothelioma in the second or third
quarter of 2020
EBV CAR T Platform
- Academic presentation of an off-the-shelf, allogeneic CD19 CAR
T clinical proof-of-principle using a partially HLA matched
Epstein-Barr virus T cell academic construct for patients with
relapsed/refractory B-cell malignancies at the 2020 Transplantation
and Cellular Therapy (TCT) Meetings to be held February 19-23 in
Orlando, Fla.
A live audio webcast of the J.P. Morgan Healthcare Conference
presentation will be available by visiting the Investors
and Media section of the Atara website. An archived replay
of the webcast will be available on the Company's website for 14
days following the live presentation.
About Atara BiotherapeuticsAtara
Biotherapeutics (@Atarabio) is a leading
off-the-shelf, allogeneic T-cell immunotherapy company developing
novel treatments for patients with cancer, autoimmune and viral
diseases. Atara’s technology platform leverages research
collaborations with leading academic institutions with the
Company’s scientific, clinical, regulatory and manufacturing
expertise. Atara’s pipeline includes tab-cel® (tabelecleucel),
which is in Phase 3 development for patients with Epstein-Barr
virus-associated post-transplant lymphoproliferative disease (EBV+
PTLD) as well as in earlier stage development for other
EBV-associated hematologic malignancies and solid tumors, including
nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting
EBV antigens believed to be important for the potential treatment
of multiple sclerosis; and next-generation chimeric antigen
receptor T-cell (CAR T) immunotherapies. The Company was founded in
2012 and is co-located in South San Francisco and Southern
California. Our Southern California hub is anchored by the
state-of-the-art Atara T-cell Operations and Manufacturing (ATOM)
facility in Thousand Oaks, California. For additional information
about the company, please visit atarabio.com.
Forward-Looking StatementsThis press release
contains or may imply "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. For example,
forward-looking statements include statements regarding: the
potential benefits and efficacy of Atara Biotherapeutics’ drug
candidates or platform; opening new clinical sites; enrollment in
the Company’s clinical studies, including the timing of enrollment
for the Company’s Phase 2 study of tab-cel® in patients with
EBV+ cancers and Phase 1b ATA188 study; the timing of, and the
Company’s ability to achieve, clinical and regulatory milestones,
including the timing of a BLA submission for tab-cel® for
patients with EBV+ PTLD; the timing and results of additional data
from the Company’s clinical trials; the timing of an IND submission
for a mesothelin-targeted CAR T; and academic presentations. These
forward-looking statements are subject to risks and uncertainties,
including those discussed in Atara Biotherapeutics' filings
with the Securities and Exchange Commission (SEC),
including in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of the Company’s most recently filed periodic reports on Form 10-K
and Form 10-Q and subsequent filings and in the documents
incorporated by reference therein. Except as otherwise required by
law, Atara Biotherapeutics disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date hereof, whether as a result of new
information, future events or circumstances or otherwise.
CONTACTS:
MediaKerry Beth DalyHead, Corporate
CommunicationsAtara
Biotherapeutics516-982-9328kdaly@atarabio.com
InvestorsJohn Craighead, Ph.D.Vice President,
Investor Relations & Corporate CommunicationsAtara
Biotherapeutics650-410-3012jcraighead@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024